Landolt A M, Osterwalder V, Landolt T A
J Endocrinol. 1987 Jun;113(3):495-9. doi: 10.1677/joe.0.1130495.
Electron microscopic morphometric evaluation of the effects of bromocriptine on human prolactinomas during and after short-term parenteral (7 days) and long-term peroral (4-6 weeks) treatment showed that a reduction in size of prolactinoma cells occurs within a few days (half-time to maximum shrinkage, 2.2 days). The number of secretory granules discharged into the intercellular space increased after short-term treatment by a factor of three but the total volume of stored secretory granules did not change significantly. The total volume of cellular lysosomes, both primary and secondary, decreased significantly to about one-half of the pretreatment value. The amount of stored lipoids, end-products of lysosomal activity, decreased in specimens treated for 7 days, but returned to pretreatment levels in specimens treated for 4-6 weeks, suggesting that lysosomal material is discharged from the cells together with the secretory material.
对溴隐亭在短期肠胃外(7天)和长期口服(4 - 6周)治疗期间及之后对人催乳素瘤影响的电子显微镜形态计量学评估显示,催乳素瘤细胞大小在数天内减小(最大收缩的半衰期为2.2天)。短期治疗后,排入细胞间隙的分泌颗粒数量增加了两倍,但储存的分泌颗粒总体积没有显著变化。初级和次级细胞溶酶体的总体积显著减少至预处理值的约一半。溶酶体活性终产物——储存脂质的量在治疗7天的标本中减少,但在治疗4 - 6周的标本中恢复到预处理水平,这表明溶酶体物质与分泌物质一起从细胞中排出。